Most material SEC filings — September 9, 2026

On September 2, 2026, Diversified Energy Company agreed to acquire Birch Permian Holdings, Inc., a Delaware corporation, through a merger with a subsidiary. The transaction includes a base cash consideration of $758.75M (less $50M deposit, plus ticking fees), concurrent acquisitions of MIP Class B units and Birch II subsidiaries by Parent, and is conditioned on closing by November 19, 2026. Consideration is subject to post-closing adjustments for leakage, effective date accounts, and title/environmental defects, with $50M deposited and escrow accounts established for dispute resolution.

AvalonBay Communities and Equity Residential completed a merger of equals on August 17, 2026, creating Vivmark Residential (NYSE: VMRK), an S&P 500 company. The combined entity operates 184,000+ apartment homes across U.S. markets with $4.4B in active development. Management will present at the Bank of America Global Real Estate Conference on September 16, 2026.

Barinthus Biotherapeutics plc filed an 8-K on 2026-09-09 disclosing termination of a material definitive agreement (Item 1.02), completion of an acquisition or disposition of assets (Item 2.01), notice of delisting or listing failure (Item 3.01), material modifications to security holder rights (Item 3.03), and changes in control of the registrant (Item 5.01). The filing document headers indicate these events occurred but specific counterparties, dollar amounts, share counts, and transaction dates are not provided in the accessible text—only item references are visible.

GameSquare IP Holdings (subsidiary of GameSquare Holdings, public market cap ~$25.4M) acquired substantially all assets of FanEngine Holdings Ltd. (UK private company) and predecessor entities Anonymous Labs Limited and Credenza, Inc. for consideration of: (1) 30% of Parent's post-closing Common Stock (Issued Shares) issued to Seller Securityholders, (2) up to 10% additional shares (Share Earnout) contingent on revenue milestones ($3M monthly or $30M annualized in first 6 months; $6M monthly or $60M annualized in months 6-18), and (3) up to $50M cash earnout over 2027-2028 (50% of Earnout Net Income above $8M in 2027, above $25M in 2028, capped $25M/year). Transaction dated September 8, 2026; Parent stockholder approval and Nasdaq listing approval required; Closing expected by December 31, 2026.

Americas Car-Mart (CRMT) reported Q1 FY2027 (ended July 31, 2026) results showing severe operational deterioration: retail unit sales fell 81.9% to 2,450 units (from 13,568 YoY); inventory collapsed 68.7% to $35.2M (from $112.5M); revenue declined 57.3% to $145.8M; net loss widened to $69.0M ($8.28/share) from $5.7M loss ($0.69/share). The company closed 60 dealerships (39% reduction to 94 locations) and shifted to wholesaling repossessed vehicles. Net charge-offs surged to 9.5% of receivables (from 6.6%). Management faces capital structure crisis: unrestricted cash dropped to $27.5M (from $47.0M in April 2026); total debt $623.9M; covenant relief amendment extended only through Sept 11, 2026; Special Committee actively evaluating strategic/financing alternatives with no transaction assured. SG&A included $13.7M in non-recurring charges ($9.6M restructuring fees, $4.1M retention awards).

Independence Realty Trust (IRET, ~$4.2B market cap) agreed to merge with Centerspace (CTRE) in an all-stock transaction dated September 8, 2026. IRET shareholders will receive one share of IRET common stock for each Centerspace share owned (Exchange Ratio to be determined), while Centerspace OP unitholders will receive IRET OP units. The deal is structured as a forward merger followed by a partnership merger, intended to qualify as a tax-free reorganization under IRC Section 368(a).

Daedalus Special Acquisition Corp. (DSAC), a $255.8M SPAC, signed a non-binding Letter of Intent on September 8, 2026 to merge with HUBX Yazilim Hizmetleri Anonim Şirketi, a Turkey-based consumer AI company founded in 2022. HubX has received a $75M investment commitment (reportedly from Point72). The transaction remains non-binding; definitive agreements, due diligence, shareholder approval, and regulatory clearance are still required.

As of August 31, 2026, PowerCompute held 323 Bitcoin valued at approximately $25.2 million (at ~$78,000/BTC), with 307 BTC pledged against an Arch credit facility with $21.9 million outstanding and 16 BTC unencumbered. August 2026 production was 7.9 BTC (flat vs. July), with seasonal curtailment generating $132,000 in energy sales. The company plans to deploy ~1,000 new miners by September 30, 2026, targeting a 7% hash rate increase to 825 PH/s.

Independence Realty Trust, Inc. (Parent) agreed to acquire Centerspace (Company), a North Dakota REIT, via merger dated September 8, 2026. Centerspace shareholders will receive Parent Common Stock at an Exchange Ratio to be determined; Company OP unitholders receive Parent OP Common Units and Preferred Units at the same Exchange Ratio. The transaction is structured as dual mergers (Company Merger and Partnership Merger) intended to qualify as a tax-free reorganization under Section 368(a) of the Code.

Wheeler Real Estate Investment Trust, Inc. (market cap ~$3.4M) filed an 8-K on September 9, 2026 reporting material modifications to rights of security holders (Item 3.03) and other events (Item 8.01). The filing itself contains no specific dollar amounts, share counts, percentages, dates of modification, counterparty names, or concrete details of what rights were modified. The actual substance of the modifications is not disclosed in this document header.

Intelligent Bio Solutions submitted a 510(k) premarket notification to the FDA on September 9, 2026, seeking clearance for its Intelligent Fingerprinting Drug Screening System for codeine detection. The submission includes clinical data demonstrating 98%+ accuracy, 94%+ sensitivity, and 100% specificity from studies conducted at three independent U.S. sites with 18,000+ hours of data collection. FDA clearance is expected to enable U.S. commercialization in the multi-billion-dollar drug screening market, where the technology is already deployed outside the U.S.

Reliance Global Group, Inc. sold 100% of Southwestern Montana Insurance Center, LLC (an insurance agency in Belgrade, Montana) to Scali, LLC for $2,625,000 cash at closing (effective September 1, 2026), based on 8.75× pro forma EBITDA of $300,000. The deal includes a potential earnout of up to 8.75× any EBITDA growth above $300,000 in the first year post-closing. Two managers (Julie and Jessica Blockey) will continue as employees under Managing Director Agreements. Buyer assumes specified liabilities; seller retains pre-closing liabilities and receivables.

Greenland Energy Co (NASDAQ: GLND, $67.6M total assets) announced on September 8, 2026, a potential offer to acquire 80 Mile PLC (AIM-listed, ticker 80M), an onshore oil and gas company. The filing is a UK City Code disclosure notice directing shareholders and warrant holders to applicable disclosure requirements under Rule 8.3. Greenland Energy has 43.73M common shares outstanding ($0.0001 par value) and 17.5M warrants ($5 strike, expiring April 29, 2031); no acquisition price, terms, or structure details are disclosed in this filing.

ARC Group International Ltd. (Hong Kong) agreed to purchase 461,354 ordinary shares and 333,333 preferred shares from CEO Conglin Deng and his entities (Bridgeforrest BVI Inc. and Alwin Creative Inc.), representing approximately 47% of Abits Group Inc.'s voting power. Total consideration: $5M cash at closing, $3.5M promissory note (12% annual interest, 12-month maturity), plus up to $5M in additional ordinary shares or cash if Abits acquires other assets within 180 days. The transaction restructures the board and grants registration and right-of-first-refusal rights to the sellers. Closing targeted August 6, 2026.

Director AKKARAJU SRINIVAS (ALMS) bought 987K shares (~$10.7M) on the open market (30% of holdings). Open-market insider purchase — historically a bullish signal.

Indaptus Therapeutics signed a stock purchase agreement dated September 8, 2026, to sell up to $24,000,000 of common stock to multiple offshore purchasers under Regulation S exemption (non-U.S. persons only). Share price = Nasdaq Minimum Price + $0.015. Closing within 15 business days, contingent on Nasdaq approval and any required stockholder vote. Company must register resale shares on Form S-1/S-3 and bear all registration costs. Purchasers limited to <4.99% beneficial ownership.

AEye announced a binding multi-million-dollar contract with Lunar Outpost (NASA-backed) to deploy Apollo lidar on the Pegasus Lunar Terrain Vehicle for Artemis missions. The company reports 9x YoY revenue growth, 2x sequential growth, 25 revenue-generating customers (+19% since Q1 2026), and expanded into sports analytics and multiple new verticals. CEO retains major shareholdings; company maintains substantial cash and near-zero debt.

Flotek raised full-year 2026 guidance on September 9, 2026 (second increase in 2026). Revenue guidance increased from $340-350M to $360-370M; Adjusted EBITDA increased from $47-51M to $50-54M. At midpoints, this represents 54% revenue growth and 58% Adj. EBITDA growth vs. 2025 actual ($237M revenue, $32.8M Adj. EBITDA). Driver: international chemistry sales surged to $10.6M in Q2 2026 (450% sequential increase from Q1), with expected H2 2026 international chemistry revenue exceeding $40M. Data Analytics segment also achieved record quarterly revenue. No material counterparties named; no new financing or structural changes disclosed.

Destination XL Group's board has reversed course and now recommends shareholders vote AGAINST the proposed merger with FullBeauty (filed Amendment No. 1 to Preliminary Proxy Statement on September 2, 2026), citing FullBeauty's deteriorating operating performance, increased indebtedness, potential negative equity, and substantial economic dilution to DXL shareholders. Q2 fiscal 2026 sales were $111.6M (down 3.4% YoY from $115.5M); net income $2.0M ($0.04/diluted share), benefiting from $4.6M tariff refund; comparable sales declined 3.5% but improved sequentially (May -5.7%, June -2.8%, July -1.9%). DXL cash and investments declined to $20.1M from $33.5M YoY due to $13.9M capital spending; no debt outstanding.

BiomX Inc. implemented a 10-for-1 reverse stock split effective September 9, 2026, automatically combining every 10 shares of common stock into 1 share; fractional shares rounded up to whole shares. The company simultaneously changed its name to Tessera Defense and Homeland Security Inc., effective September 11, 2026. No counterparties, financing, or operational changes are disclosed—this is purely a capital structure and corporate identity restructuring.

Opus Genetics announced positive 3- and 6-month results from low-dose Cohort 1 (5 participants) of its BIRD-1 Phase 1/2 trial of OPGx-BEST1 for BEST1-related retinal diseases. All 5 participants showed clinically meaningful visual improvements with no serious adverse events; 75% met the FDA-aligned microperimetry endpoint (≥3 dB improvement in ≥5 loci). In August 2026, FDA aligned on this microperimetry endpoint plus patient-reported outcome as potential pivotal trial endpoint. Cohort 2 (8 participants, higher dose 4.5×10⁹ vg/eye) is over-enrolled with dosing expected Q4 2026 and 3-month data Q2 2027; Phase 3 dosing expected 2027. Cash runway extends into 2029.

Pyxis Oncology announced positive updated Phase 1 monotherapy data for MICVO (micvotabart pelidotin) in second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma (2L+ R/M HNSCC) as of August 18, 2026. In 33 efficacy-evaluable patients dosed at 5.4 mg/kg Q3W with dose cap: confirmed objective response rate 36% (12/33), disease control rate 94% (31/33), median progression-free survival 6.2 months (95% CI 4.8–8.8), and 12-month overall survival probability 79% (95% CI 58.1–90.3). No new safety signals observed; dose cap reduced adverse events in high body-weight patients. Company plans Phase 3 'Headliner' trial initiation in mid-2027; FDA/EMA End of Phase 2 meeting expected Q1 2027.

Serina's independent Safety Monitoring Committee approved advancement of SER-252 (long-acting apomorphine for advanced Parkinson's disease) from Cohort 1 to Cohort 2 after blinded review. Cohort 1 (8 patients, lowest dose) showed sustained pharmacokinetic profile consistent with design and sustained motor function improvements on exploratory measures; safety/tolerability supported escalation. Topline single-ascending-dose data expected H1 2027.

Tenax's Phase 3 LEVEL trial of oral levosimendan (TNX-103) for PH-HFpEF failed its primary endpoint (6-minute walk distance [6MWD] improvement: 3.5 m vs placebo, p=0.63). However, in pre-specified subgroup analysis, patients with baseline 6MWD ≤333 m showed +26.3 m improvement vs placebo (p=0.0112). NT-proBNP fell 49% vs placebo (p=0.0001); right ventricular systolic pressure declined 4.9 mmHg (p=0.0090). Safety profile was acceptable with dose-limiting headache, palpitations, and hypotension. Tenax plans to enrich LEVEL-2 entry criteria to favor sicker patients with lower baseline 6MWD.

On September 9, 2026, Nasdaq granted Iveda Solutions (NASDAQ: IVDA) an additional 180-calendar-day compliance period through March 1, 2027, to restore its stock price above the $1.00 minimum bid price requirement. The company must maintain a closing bid of at least $1.00 for 10 consecutive business days to regain compliance and has not ruled out a reverse stock split. Iveda says it remains focused on commercial execution across AI video intelligence, autonomous aerial systems, and connected-care technologies.

On June 16, 2026, AIxCrypto Holdings, Inc. (market cap ~$5.6M) entered into a Common Shares Purchase Agreement with Gold King Arthur Holding Limited (Hong Kong), enabling up to $50M in volume-weighted average price (VWAP) purchases of common stock over 24 months. The company may issue up to 4,044,975 shares (19.99% of outstanding) at 93% of the 3-day VWAP minus 7% discount, with Gold King Arthur retaining a 3% draw fee. As of August 31, 2026, company projects ~$3.48M in gross proceeds based on $0.8595 VWAP. The arrangement requires shareholder approval (received July 28, 2026, pending effectiveness) to issue shares beyond the initial 4M-share cap. Stock closed at $0.69 on September 8, 2026.

Alcoa announced a proposed offering of $2.6 billion in senior notes (due 2034 and 2036) issued by subsidiaries Alumina Pty Ltd and Alcoa Nederland Holding B.V., guaranteed by Alcoa and certain subsidiaries. Net proceeds, combined with cash on hand, will fund approximately $3.1 billion cash consideration to acquire South32's bauxite, alumina, and aluminum smelter operations (AliGroup), plus related fees and transaction costs. Pro forma combined company shows assets of $22.1 billion, total debt of $5.4 billion, and LTM adjusted EBITDA of $3.1 billion as of June 30, 2026.

Tenon Medical repaid in full its $5.16M aggregate principal convertible promissory notes (issued March 11, 2026, maturing September 11, 2026) ahead of the September 11, 2026 maturity date. The company stated the repayment strengthens its balance sheet, eliminates conversion dilution risk, and preserves financial flexibility for commercial initiatives. No new financing details, debt terms, or cash position metrics are disclosed.

NN Inc, a $74.4M market-cap precision manufacturer, raised its 2026 guidance at a September 10, 2026 investor conference. Net sales guidance increased to $470M (from $460–$480M range, +10% vs. 2025's $422M); Adjusted EBITDA guidance raised to $60M ($55–$65M range, +22% vs. 2025's $49M); and new business wins guidance raised to $100M ($90–$110M range, +29%). The company reported 1H 2026 net sales of $247.2M (+16% YoY) and Adjusted EBITDA of $32.1M (+35% YoY). Key wins include $12–15M firearms accessories from Tier 1 defense supplier, robotic-assisted surgery platform (potential to double medical business from $15M to $25–30M), and $47M in data center liquid cooling awards YTD with $120M prospecting pipeline. Management expects capex of $35–40M annually (30 cents per sales dollar) and projects 2030 sales of $600–650M with 22% adjusted gross margin and 14% EBITDA margin.

Aspire Biopharma Holdings, Inc. changed its legal name to Aspire-Lakewood Holdings, Inc. (effective September 9, 2026) and the Board authorized a $10 million share repurchase program. The authorization reflects confidence following the acquisition of Dura Control Systems Corp. (DCSC), which generated $209.5M revenue and $22.3M Adjusted EBITDA in 2025, and $103.9M revenue with $10.5M Adjusted EBITDA in the first half of 2026. The company has approximately 1.5 million shares outstanding; at current metrics, the $10M buyback represents ~58% of market cap.

NorthWestern Energy (NWE, $3.1B market cap) and Black Hills Corporation are pursuing a merger announced in 2024. As of September 2026, Nebraska and South Dakota have granted unanimous regulatory approval (May 2026 and June 2026, respectively); FERC approved in May 2026; both shareholders approved in April 2026; HSR cleared April 2026. Montana regulatory approval remains pending (hearing concluded May 2026, final briefs submitted July 2026). Combined entity would serve 2.2M customers across multiple jurisdictions, target $12B rate base, and increase EPS growth guidance from 4-6% to 5-7%. No acquisition price disclosed in filing; no counterparty dollar amounts specified.

Sysco reaffirmed FY27 sales growth guidance of 6–7% (~$90B midpoint) and raised adjusted EPS growth guidance to 9–11% (high-end of prior algorithm). Company introduced a $500M annualized AI/tech-powered efficiency program by FY29, including ~$100M net cost out in FY27. The Jetro Restaurant Depot acquisition (pending regulatory approval) is expected to drive material accretion: 1.5x–mid-to-high single-digit Year 1 EPS accretion and low-to-mid-teens Year 2 accretion, with $250M in synergies. Pro forma combined entity targets 4–7% sales growth, 9–11% adj. EPS growth, and 55% FCF conversion.

SRX Global Inc. secured written consent from its Series C preferred stock holder (who purchased 3,579 shares for $2.825M on August 27, 2026) to implement a repurchase plan authorizing up to 10M common shares or 50% of outstanding shares, capped at $20M aggregate spend through July 7, 2027. The consent waives restrictions in the Securities Purchase Agreement and Certificate of Designations that normally prohibit redemptions/repurchases without preferred holder approval. The company will pay $5,000 in legal fees to the holder's counsel.

iPower Inc. filed a Form S-1/A registering 9,636,864 common shares (par $0.001) convertible from $3,099,444 aggregate principal of Series A senior secured convertible notes issued to a selling stockholder under a Securities Purchase Agreement dated December 22, 2025 (amended July 7, 2026). The notes were originally sold in a private Reg D placement. Legal counsel (Dorsey & Whitney) opined the converted shares will be validly issued, fully paid, and non-assessable.

Global Interactive Technologies (market cap ~$4.0M) signed a share purchase agreement on September 1, 2026 to acquire 100% of AST Co., Ltd. from Kim Gahee for KRW 10,000,000 (~$7,500 USD) in share purchase price plus a shareholder loan of up to KRW 1,140,000,000 (~$855K USD) to cover the target's existing liabilities. GITS will also issue performance-linked warrants valued at KRW 400,000,000 (~$300K USD) to three individuals (Kim Taeho, Kim Gahee, and Park Yigeun). Closing is conditional on due diligence, board approvals, and SEC/Nasdaq compliance; the transaction is not yet effective pending satisfaction of multiple conditions precedent.

TruGolf Holdings, Inc. (Parent) amended its August 17, 2026 acquisition agreement with Polymath Research Inc. and subsidiary 18141991 Canada Inc. The amendment, effective August 17 and executed September 8, 2026, modified Section 1.1(v) of the Acquisition Agreement to redefine the calculation of 'Closing Shares of Parent Convertible Preferred Stock' from an unspecified prior formula to: ($140,000,000 minus (Closing Shares of Parent Common Stock × Parent Closing Price)) ÷ $1,000. The amendment does not disclose the deal value, share counts, stock price, or specific financial terms beyond this formula adjustment.

WRAP Technologies amended employment agreements for Scot Cohen (CEO/Executive Chairman) and Jared Novick (President/COO) on September 2, 2026. Cohen receives 4M restricted shares with market-cap vesting targets ($150M–$506.25M); Novick receives 2M restricted shares with identical vesting milestones. Both awards are contingent on stockholder approval by March 15, 2027 to increase authorized plan shares (1.6M and 800K shares respectively become void if approval fails). Equity is performance-based, vesting only when 45-day trading-day thresholds are met at specified market caps. Both executives retain $200K base salary; Cohen also gets 12-month severance plus COBRA; Novick gets $75K sign-on bonus.

Multiple Ares Management-affiliated entities (ASOF HOS GP LLC, ASOF HOS AIV 1 & 2 LP, ASSF IV entities, and others) jointly filed a Schedule 13D on September 9, 2026, indicating a significant shareholding in Hornbeck Offshore Services. The filing was executed by Evan Hoole (Ares Managing Director) and Anton Feingold (Ares authorized signatory), with governance by senior Ares leaders including CEO Michael Arougheti and co-founders. Specific share count, ownership percentage, and acquisition price are not disclosed in this joint filing agreement excerpt.

GoPro issued $20M in aggregate principal amount of senior secured notes (third priority lien) and warrants for 25.7M Class B shares to two buyers: Terrapin Trust ($5M notes, 6.4M warrants) and Woodman Family Trust ($15M notes, 19.3M warrants). Effective July 1, 2026, with proceeds used to pay supplier payables. Warrants exercise price $0.7280/share, exercisable from Jan 2027 or upon Change of Control announcement through July 2029.

Incannex commenced patient dosing in DReAMzz, a Phase 2 dose-optimization study of IHL-42X in obstructive sleep apnea across 13 U.S. clinical sites on August 25, 2026. The U.S. Patent and Trademark Office granted a composition and methods patent covering IHL-42X with baseline expiry July 9, 2040. As of August 31, 2026, the company held approximately $70 million in cash and no debt, including A$11.2 million in non-dilutive R&D tax incentive capital received during 2026.

Cocrystal Pharma announced last subject dosed in Phase 1b randomized, double-blind, placebo-controlled challenge study of CDI-988 for norovirus prevention/treatment at Emory University. No serious adverse events reported; primary endpoint is efficacy in reducing clinical symptoms; preliminary results expected late 2026 or early 2027. CDI-988 previously showed safety up to 1200 mg dose in Phase 1 Australia trial.

Xeris Biopharma hosted a webinar on September 9, 2026, detailing its comprehensive clinical development program for XP-8121, an investigational once-weekly subcutaneous levothyroxine for hypothyroidism. The Cornerstone Phase 3 registrational study will enroll 500 patients across 50+ U.S. sites over 54 weeks with a 15% non-inferiority margin versus daily oral levothyroxine; topline results expected late 2028, with FDA approval and commercial launch anticipated in 2030. The company projects XP-8121 peak net revenue potential of $1–3 billion, targeting a 3–5 million patient population with uncontrolled hypothyroidism.

Chief Growth Officer Glavine Paul (CYBN) bought 90K shares (~$1.0M) on the open market (2.2% of holdings). Open-market insider purchase — historically a bullish signal.

Gloo reported Q2 2026 revenue of $46.6M (188% YoY growth), beating guidance of $44.0M. Net loss narrowed to $21.2M vs. $44.1M YoY. Adjusted EBITDA improved to negative $8.3M (vs. negative $11.5M in Q1 2026), marking third consecutive quarterly improvement. Company raised FY2026 revenue guidance to $200M and extended $13.2M senior secured loan by one year to April 2028. Five acquisitions announced since IPO; Cedarstone and remaining Midwestern stake acquired in August 2026.

CHIEF EXECUTIVE OFFICER Barry John F (PSEC) bought 1.2M shares (~$2.7M) on the open market (1.3% of holdings). Open-market insider purchase — historically a bullish signal.

Chief Executive Officer Rodgers Thurman J (SPWR) bought 7.9M shares (~$2.0M) on the open market (18% of holdings). Open-market insider purchase — historically a bullish signal.

Chief Executive Officer Meeks Danny (GWAV) bought 2.2M shares (~$8.0M) on the open market (50% of holdings). Open-market insider purchase — historically a bullish signal.

Executive Chair So Eric H. L. (CYBN) bought 95K shares (~$1.1M) on the open market (2.2% of holdings). Open-market insider purchase — historically a bullish signal.

Sysco reaffirmed fiscal 2027 guidance (9–11% adjusted EPS growth on 53-week basis, ~$90B net sales at 6–7% growth) and introduced a $500 million multi-year AI-powered cost-reduction program targeting $100M savings in FY2027 and full $500M by FY2029. The company simultaneously raised mid-term targets for fiscal 2028–2029 to 4–7% net sales growth and 9–11% adjusted EPS growth (previously 6–8%), expanding the upper bound for sales from 6% to 7%.

Korn Ferry reported Q1 FY'27 fee revenue of $756.5M (up 7% YoY), with net income of $69.0M and adjusted diluted EPS of $1.43 (up 9% YoY). The company completed its acquisition of AMS on September 1, 2026, which CEO Burnison describes as meaningfully expanding Workforce Solutions. Integration costs totaled $7.6M in Q1. Q2 FY'27 guidance: fee revenue $860M–$878M; adjusted EBITDA margin 16.8%–17.2%; adjusted diluted EPS $1.30–$1.40 (including two months of AMS contribution).